DURECT (DRRX) Stock Price, News & Analysis

Company Overview

DURECT Corporation is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for chronic diseases and acute conditions. Leveraging proprietary drug delivery platforms, the company is advancing a pipeline of small molecule and injectable products aimed at addressing pain management, liver disease and other areas of unmet medical need. DURECT’s research emphasizes novel mechanisms of action as well as extended‐release formulations to improve patient convenience and treatment outcomes.

The company’s two principal platforms, ORADUR® and SABER®, enable customized release profiles for both oral and injectable therapies. Through these technologies, DURECT is developing POSIDUR®, an extended‐release meloxicam injection for post‐operative pain, which has been licensed to international partners for regulatory filing in key markets. In addition, DURECT’s lead internally developed compound, DUR-928, is a small molecule in clinical evaluation for acute organ injuries and chronic liver diseases such as alcoholic hepatitis and nonalcoholic steatohepatitis (NASH).

Since its founding in 1998 and its subsequent initial public offering in 2004, DURECT has established collaborative relationships with global pharmaceutical companies to advance product candidates across multiple geographies. Licensing partnerships include agreements with Grünenthal for ex-U.S. commercialization of POSIDUR® and with Luye Pharma in Greater China. These alliances support DURECT’s strategy of combining in-house innovation with partner expertise to accelerate clinical development and expand market reach.

Headquartered in Cupertino, California, DURECT is led by a management team with extensive experience in drug development and commercial operations. President and Chief Executive Officer James E. Brown oversees corporate strategy and pipeline progression, supported by senior executives in research, regulatory affairs and business development. With an emphasis on scientific rigor and strategic partnership, DURECT continues to drive its mission of delivering differentiated therapies for patients worldwide.

Key Stats

• Today's Range: $0.62 to $0.69
• 50-Day Range: $0.50 to $0.73
• 52-Week Range: $0.48 to $1.74
• Volume: 44,069 shs
• Average Volume: 41,276 shs
• Market Capitalization: $19.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

DURECT Stock Analysis - MarketRank™

DURECT scored higher than 11% of companies evaluated by MarketBeat, and ranked 886th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for DURECT.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for DURECT are expected to decrease in the coming year, from ($0.50) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DURECT is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DURECT is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DURECT has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.90% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in DURECT has recently increased by 2.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DURECT does not currently pay a dividend.

Dividend Growth

DURECT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

2.90% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in DURECT has recently increased by 2.53%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for DURECT this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for DRRX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added DURECT to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DURECT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of DURECT is held by insiders.

Percentage Held by Institutions

Only 28.03% of the stock of DURECT is held by institutions.

DRRX Stock Analysis - Frequently Asked Questions

How have DRRX shares performed this year?

DURECT's stock was trading at $0.75 at the beginning of the year. Since then, DRRX stock has decreased by 15.1% and is now trading at $0.6367.

How were DURECT's earnings last quarter?

DURECT Corporation (NASDAQ:DRRX) issued its quarterly earnings results on Wednesday, March, 26th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.12. The specialty pharmaceutical company earned $2.30 million during the quarter, compared to the consensus estimate of $6.91 million. DURECT had a negative trailing twelve-month return on equity of 267.36% and a negative net margin of 91.54%.
Read the conference call transcript.

When did DURECT's stock split?

DURECT shares reverse split on the morning of Tuesday, December 6th 2022.The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 3/26/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRRX
• CIK: 1082038
• Web: www.durect.com
• Phone: (408) 777-1417
• Fax: 408-777-3577
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.32 million
• Net Margins: -91.54%
• Pretax Margin: -305.34%
• Return on Equity: -267.36%
• Return on Assets: -64.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: $2.03 million
• Price / Sales: 9.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 31,040,000
• Free Float: 30,049,000
• Market Cap: $20.11 million
• Optionable: Optionable
• Beta: 0.64